Hyperinsulinemia in Prediabetes Mediated by Interleukin-1β

Summary

The goal of this clinical study is to test whether postprandial insulin secretion in subjects with prediabetes is mediated by Interleukin-1β and may be influenced by administration of the medicinal product anakinra (Kineret®). The main question it aims to answer is whether there is a difference in insulin secretion following a standardized mixed-meal test under anakinra compared to placebo.

Timeline

Start

2023-06-15

Primary completion

2024-05-17

Completion

2024-05-17

Drugs

Indications